ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

A Phase 2 Study of ZK219477 (ZK-EPO) in Patients With Breast Cancer and Brain Metastases

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00496379

Enrollment

Registered

2007-07-04

Start date

2007-07-31

Completion date

2012-01-31

Last updated

2013-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, CNS Disease

Keywords

metastatic breast cancer, invasive breast cancer, brain metastases, ZK-EPO

Brief summary

The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer. ZK219477 is a chemotherapy drug that is thought to work by interfering with the ability of cancer cells to grow and divide. It is a part of a group of drugs called epothilones which appear to cause shrinkage of cancer in some patients with breast cancer. It is generally difficult for chemotherapy to enter the brain. However, it is believed that ZK219477 crosses into the brain. We are also studying whether an investigational MRI scan procedure may eventually help to predict which patients will benefit from ZK219477.

Detailed description

* Participants will be given ZK219477 intravenously over approximately 30 minutes every three weeks. * During all treatment cycles a physical exam and questions about the participants general health and specific questions about any problems they may be having will be performed. * At least every three weeks blood tests will be done to assess the effect of ZK219477 on the body. * After every 2 cycles of treatment, participants will have additional scans to assess the effect of ZK219477 on their cancer. This will include a CT scan of the abdomen, chest, and pelvis, and an MRI of the brain. * At the time of the standard MRI, participants will be asked to undergo an additional MRI sequence, which means they will be in the MRI machine for approximately 15-20 more minutes.

Interventions

DRUGZK219477

Given intravenously over approximately 30 minutes once every 3 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must have histologically or cytologically invasive breast cancer, with metastatic disease at the time of screening * Measurable Central Nervous System (CNS) disease, as defined as at least one lesion \> or equal too 10mm in longest dimension * New or progressive CNS lesions after at least one prior standard CNS-directed therapy for treatment of brain metastases, which could include surgical resection, whole brain radiotherapy (WBRT), and/or stereotactic radiosurgery (SRS). Patients must have received prior WBRT, SRS or both. * Patient has been evaluated by a radiation oncologist, who feels that the plan to evaluate systemic chemotherapy in place of additional brain radiotherapy is an acceptable option * No increase in corticosteroid use in the week prior to study entry * Any number prior lines of chemotherapy for metastatic breast cancer * 18 years of age of older * Life expectancy of greater than 12 weeks * ECOG Performance Status 0-2 * Patients must have normal organ function as outlined in the protocol

Exclusion criteria

* Patients who have had chemotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier * Patients who have had XRT within 3 weeks prior to entering the study or those who have not recovered from adverse events due to XRT * Patients may not be receiving any other investigational agent * Patients may not be receiving any cancer-directed therapy * Prior treatment with investigational chemotherapy for brain metastases * Prior treatment with epothilone for metastatic breast cancer * Leptomeningeal carcinomatosis as the only site of CNS involvement. * Concurrent treatment with an enzyme inducing antiepileptic drug, including phenytoin, carbamezepine, phenobarbital, or oxacarbazepine * More than 2 seizures over the last four weeks prior to study entry * Known contraindication to MRI or gadolinium contrast, such as cardiac pacemaker, ocular foreign body, or shrapnel * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant or breastfeeding women.

Design outcomes

Primary

Measure	Time frame	Description
Objective Response Rate in the Central Nervous System (CNS)	2 years	Objective response rate is defined as at least a 50 percent reduction in the Central Nervous system target lesion volume compared to the lesion volume at baseline.

Secondary

Measure	Time frame	Description
Number of Subjects With Adverse Events (Any Grade)	2 years	Adverse events per NCI CTCAE
Objective Response Rate in Non-Central Nervous System (CNS) Sites	2 years	Non-CNS response rate (according to RECIST 1.0) limited to patients with measurable non-CNS disease
Time to Progression at Any Site.	2 years	Time from date of registration until the date of the first documentation of progression or date of death (from any cause),whichever came first, up to 2 years from registration. Progression is defined as either progression in the Central Nervous system (CNS) according to volumetric measurement (Freedman et al. 2011) and /or progression in non-Central Nervous System lesion Measured by RECIST 1.0
Clinical Benefit Rate.	2 years	CBR = CR + PR + SD \> 24 weeks in CNS with at least stable non-CNS disease

Countries

United States

Participant flow

Recruitment details

Patients were enrolled at Dana-Farber/Harvard Cancer Center between 8/1/2007-10/29/2009.

Participants by arm

Arm	Count
Sagopilone Either 16 mg/m2 or 22 mg/m2 IV Q3W	15
Total	15

Baseline characteristics

Characteristic	Sagopilone
Age, Categorical <=18 years	0 Participants
Age, Categorical >=65 years	2 Participants
Age, Categorical Between 18 and 65 years	13 Participants
Age Continuous	50.3 years STANDARD_DEVIATION 12.7
Region of Enrollment United States	15 participants
Sex: Female, Male Female	15 Participants
Sex: Female, Male Male	0 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	15 / 15
serious Total, serious adverse events	1 / 15

Arm	Measure	Value (MEDIAN)
Sagopilone	Time to Progression at Any Site.	1.4 months

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026